CIS, on the other hand, is considerably more aggressive and associated with alterations of tumor protein 53 (TP53) and retinoblastoma (RB) pathways [6], alterations that also characterize invasive tumors (T2–T4), which acquire further molecular events affecting vascular endothelial growth factors (VEGF), cadherins, matrix metalloproteinases (MMPs), resulting in extracellular matrix remodeling, angiogenesis, and metastatic spread [7]. The gene discussed is VEGFA; the disease is in situ carcinoma.